Today: 29 June 2026
Browse Category

NASDAQ:APLS 30 October 2025 - 21 May 2026

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Biogen has finished its acquisition of Apellis Pharmaceuticals, and trading in the APLS ticker has ceased. Apellis is now a wholly owned unit of Biogen after the buyout. This is in focus now since the cash payout is done, but the remaining value isn’t settled. Former Apellis holders picked up $41 a share plus a CVR. That CVR, or contingent value right, could mean more money if Syfovre—Apellis’ drug for geographic atrophy, a late-stage vision-loss disease—hits certain sales goals.
21 May 2026
···
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Pharmaceuticals is off the Nasdaq tape now that Biogen has finished its buyout. The focus moves to Biogen and if it can pull enough revenue from Syfovre and Empaveli to make the acquisition pay. APLS shares aren’t in the public’s hands anymore. Investors got $41 in cash per share plus a CVR tied to sales of Syfovre, Apellis’ drug for geographic atrophy, a type of advanced dry macular degeneration. The CVR could pay more if certain sales goals are met. Biogen said Apellis is now a wholly owned unit. Apellis shares stopped trading on Nasdaq after the deal closed.
20 May 2026
····
Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen wrapped up its purchase of Apellis Pharmaceuticals last week, ending Apellis’ time as a listed company as its shares stopped trading on Nasdaq. Each Apellis holder will get $41 per share in cash and one contingent value right. The CVR will pay out if certain future sales targets are hit. APLS is moving to a new phase. Last week was all tender results, delisting, and payout details, but this week is about settlement. The Monday open is no longer the focus.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Cambridge, Massachusetts, May 15, 2026, 10:08 EDT Biogen said Thursday it has wrapped up its purchase of Apellis Pharmaceuticals, bringing Apellis under its wing as a fully owned subsidiary. The deal takes Apellis off the Nasdaq as an independent biotech, and hands Biogen ownership of its two approved drugs, which join Biogen’s rare-disease division.
15 May 2026
···
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

CAMBRIDGE, Massachusetts, May 14, 2026, 10:21 Biogen wrapped up its takeover of Apellis Pharmaceuticals on Thursday, bringing an end to Apellis’ time as an independent Nasdaq-listed biotech. With the Waltham, Massachusetts firm now a wholly owned Biogen subsidiary, Apellis shares stopped trading on Nasdaq following completion of the tender offer and merger.
14 May 2026
···
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Shares of Apellis Pharmaceuticals hovered close to Biogen’s $41-per-share bid on Wednesday, following news of the $5.6 billion cash-and-contingent deal announced a day earlier. The stock last traded at $40.23 in the U.S. session. This deal gives Apellis shareholders about a 140% premium over where the stock closed on March 30, and drops two marketed drugs and a nephrology sales team directly into Biogen’s hands. Biogen, looking to push past its sluggish multiple sclerosis segment, sees Apellis’ kidney portfolio as a stepping stone for its upcoming kidney drug felzartamab, now in late-stage trials.
1 April 2026
···
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals, a biotech focused on complement-mediated diseasesgurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last yearinvesting.com. This record top-line was boosted by a one-time $275 M licensing deal with partner Sobiinvesting.com, which paid Apellis upfront for future ex-U.S. royalties on Aspaveli. Thanks largely to this deal, Apellis swung to a net profit of $215.7 Mmarkets.businessinsider.com. However, the market’s reaction was harsh. Shares of APLS plunged over 20% after earnings – falling to around $24 – as investors focused on management’s guidance that the current profitability is not yet permanentinvesting.com. Despite beating analyst forecastsinvesting.com, Apellis indicated it expects to return to net losses in coming quarters, once the one-off Sobi windfall is absorbed. This cautious outlook spooked traders, sending the stock on a steep slide in Thursday’s session. The sharp drop erased a rally that had lifted Apellis shares to about $29–30 in late Octoberdirectorstalkinterviews.com. Prior to earnings, the stock had climbed on optimism from an analyst upgrade and data updates, but the post-earnings “whiplash” highlights Wall Street’s jitters about Apellis’s trajectory
30 October 2025
·

Stock Market Today

  • Sugar Jumps as India Monsoon Falters; Brazil Output Squeezed
    June 29, 2026, 2:56 PM EDT. Sugar prices moved higher with July NY sugar up 2.58%, hitting a three-week top. August London white sugar added 2.13%, trading at a 9.5-month high. Traders pointed to weak monsoon rains in India, the No. 2 sugar producer, which got 42% less rain than normal and faces its softest monsoon in 11 years. Brazil's mills are expected to produce less sugar too, as more cane is shifted to ethanol, bringing the share down to 41.4% from 50.1% a year ago. Global supply fears built after trader Czarnikow moved its forecast from a surplus to a small deficit. A strong El Niño could further dent harvests in Brazil, India, and Thailand.
Go toTop